AIMS: The EndoCost study aims to calculate the costs of endometriosis from a societal perspective. METHODS: This multicentre, prevalence-based cost-of-illness analysis aggregates data on endometriosis costs and quality of life from a prospective hospital questionnaire and from both retrospective and prospective patient questionnaires. The EndoCost study comprises 12 representative tertiary care centres involved in the care of women with endometriosis in 10 countries. The sample includes patients with a laparoscopic and/or histological diagnosis of endometriosis and with at least 1 patient contact related to endometriosis during 2008. The EndoCost study measures direct healthcare costs (e.g. costs of medication, physician visits), direct non-healthcare costs (e.g. transportation costs), and indirect costs of productivity loss. Cost questions are developed specifically for the purpose of the EndoCost study. Quality of life is measured using the EuroQol-5D and relevant parts of the Global Study of Women's Health instruments. Both aggregate analyses and country-specific analyses are planned for total costs per patient. Costs are broken down into cost drivers and into the various payers that incur costs. CONCLUSIONS: The cost estimates provided by the EndoCost cost-of-illness analysis may be used to justify the prioritisation of future research in endometriosis.
AIMS: The EndoCost study aims to calculate the costs of endometriosis from a societal perspective. METHODS: This multicentre, prevalence-based cost-of-illness analysis aggregates data on endometriosis costs and quality of life from a prospective hospital questionnaire and from both retrospective and prospective patient questionnaires. The EndoCost study comprises 12 representative tertiary care centres involved in the care of women with endometriosis in 10 countries. The sample includes patients with a laparoscopic and/or histological diagnosis of endometriosis and with at least 1 patient contact related to endometriosis during 2008. The EndoCost study measures direct healthcare costs (e.g. costs of medication, physician visits), direct non-healthcare costs (e.g. transportation costs), and indirect costs of productivity loss. Cost questions are developed specifically for the purpose of the EndoCost study. Quality of life is measured using the EuroQol-5D and relevant parts of the Global Study of Women's Health instruments. Both aggregate analyses and country-specific analyses are planned for total costs per patient. Costs are broken down into cost drivers and into the various payers that incur costs. CONCLUSIONS: The cost estimates provided by the EndoCost cost-of-illness analysis may be used to justify the prioritisation of future research in endometriosis.
Authors: Kasra Khalaj; Jessica E Miller; Harshavardhan Lingegowda; Asgerally T Fazleabas; Steven L Young; Bruce A Lessey; Madhuri Koti; Chandrakant Tayade Journal: JCI Insight Date: 2019-09-19
Authors: L V Farland; S A Missmer; A Bijon; G Gusto; A Gelot; F Clavel-Chapelon; S Mesrine; M C Boutron-Ruault; M Kvaskoff Journal: Hum Reprod Date: 2017-08-01 Impact factor: 6.918
Authors: Marina Kvaskoff; Fan Mu; Kathryn L Terry; Holly R Harris; Elizabeth M Poole; Leslie Farland; Stacey A Missmer Journal: Hum Reprod Update Date: 2015-03-11 Impact factor: 15.610
Authors: Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano Journal: Front Pharmacol Date: 2018-09-19 Impact factor: 5.810
Authors: Marc H Schreinemacher; Walter H Backes; Jos M Slenter; Sofia Xanthoulea; Bert Delvoux; Larissa van Winden; Regina G Beets-Tan; Johannes L H Evers; Gerard A J Dunselman; Andrea Romano Journal: PLoS One Date: 2012-03-22 Impact factor: 3.240